Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 4, 2014, Pages 1078-1090

  Buglione Corbett, Rachel ^a   Pouliot, Kimberly ^a   Marty Roix, Robyn ^a   Li, Wei ^a   West, Kim ^a   Wang, Shixia ^a   Morelli, Adriana Baz ^b   Lien, Egil ^a   Lu, Shan ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b CSL LIMITED   (Australia)

Author keywords

Adjuvants; Antibody; Cytokines; HIV 1; ISCOMATRIX ; MyD88; Prime boost

Indexed keywords

CYTOKINE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ISCOMATRIX; ISCOMATRIX VACCINE; MYELOID DIFFERENTIATION FACTOR 88; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA; CHOLESTEROL; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOLOGICAL ADJUVANT; MYD88 PROTEIN, MOUSE; PHOSPHOLIPID; SAPONIN; SUBUNIT VACCINE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DNA IMMUNIZATION; DRUG EFFICACY; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INNATE IMMUNITY; MOUSE; NONHUMAN; RABBIT; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; DRUG COMBINATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGY; MALE; METABOLISM; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CHOLESTEROL; CYTOKINES; DRUG COMBINATIONS; FEMALE; HIV ANTIBODIES; HIV-1; IMMUNIZATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHOLIPIDS; RABBITS; SAPONINS; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 84899852225     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27907     Document Type: Article

References (31)

1. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327:291-5; PMID:20075244; http://dx.doi.org/10. 1126/science.1183021
2. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140:805-20; PMID:20303872; http://dx.doi.org/10.1016/j.cell.2010.01.022
3. Drane DCG, Gittleson C, Boyle J, Maraskovsky E. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 2007; 6:761-72; PMID:17931156; http://dx.doi.org/10.1586/14760584.6.5.761
4. Sjölander A, Cox JC. Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines. Adv Drug Deliv Rev 1998; 34:321-38; PMID:10837684; http://dx.doi.org/10.1016/S0169-409X(98)00046-5
5. Sjölander A, Drane D, Maraskovsky E, Scheerlinck JP, Suhrbier A, Tennent J, Pearse M. Immune responses to ISCOM formulations in animal and primate models. Vaccine 2001; 19:2661-5; PMID:11257406; http://dx.doi.org/10. 1016/S0264-410X(00)00497-7
6. Evans TG, McElrath MJ, Matthews T, Montefiori D, Weinhold K, Wolff M, Keefer MC, Kallas EG, Corey L, Gorse GJ, et al.; NIAID AIDS Vaccine Evaluation Group. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 2001; 19:2080-91; PMID:11228380; http://dx.doi.org/10.1016/S0264-410X(00)00415-1
7. Waite DC, Jacobson EW, Ennis FA, Edelman R, White B, Kammer R, Anderson C, Kensil CR. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001; 19:3957-67; PMID:11427271; http://dx.doi.org/10.1016/S0264-410X(01)00142-6
8. McKenzie A, Watt M, Gittleson C. ISCOMATRIX() vaccines: Safety in human clinical studies. Hum Vaccin 2010; 6:237-46; PMID:20595811; http://dx.doi.org/ 10.4161/hv.6.3.10754
9. Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol 2012; 61:935-43; PMID:22442293; http://dx.doi.org/10.1099/jmm.0.040857-0
10. Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, Morelli AB, Clausen BE, Dauer M, Eigler A, et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol 2011; 187:55-63; PMID:21613613; http://dx.doi.org/10.4049/jimmunol.1004114
11. Wilson NS, Yang B, Morelli AB, Koernig S, Yang A, Loeser S, Airey D, Provan L, Hass P, Braley H, et al. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol Cell Biol 2012; 90:540-52; PMID:21894173; http://dx.doi.org/10.1038/icb.2011.71
12. Pearse MJ, Drane D. ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses. Vaccine 2004; 22:2391-5; PMID:15193400; http://dx.doi.org/10.1016/j.vaccine.2003.12.031
13. Bansal A, Jackson B, West K, Wang S, Lu S, Kennedy JS, Goepfert PA. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 2008; 82:6458-69; PMID:18448544; http://dx.doi.org/10.1128/JVI.00068-08
14. Kennedy JS, Co M, Green S, Longtine K, Longtine J, O'Neill MA, Adams JP, Rothman AL, Yu Q, Johnson-Leva R, et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 2008; 26:4420-4; PMID:18588934; http://dx.doi.org/10.1016/j.vaccine.2008.05.090
15. Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Cristillo A, et al. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 2005; 34:226-36; PMID:16128917; http://dx.doi.org/10.1111/j.1600- 0684.2005.00120.x
16. Buglione-Corbett R, Pouliot K, Marty-Roix R, West K, Wang S, Lien E, Lu S. Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy. PLoS One 2013; 8:e74820; PMID:24019983; http://dx.doi.org/10.1371/journal.pone.0074820
17. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-25; PMID:16051804; http://dx.doi.org/10.1128/JVI.79.16.10108-10125.2005
18. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006; 80:11776-90; PMID:16971434; http://dx.doi.org/10.1128/JVI.01730-06
19. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26:3947-57; PMID:18724414; http://dx.doi.org/10.1016/j.vaccine.2007.12.060
20. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011; 3:920-40; PMID:21994762; http://dx.doi.org/10.3390/v3060920
21. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, et al.; Ministry of Public Health-Thai AIDS Vaccine Evaluation Group Collaborators. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012; 188:5166-76; PMID:22529301; http://dx.doi.org/10.4049/jimmunol.1102756
22. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al.; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20; PMID:19843557; http://dx.doi.org/10. 1056/NEJMoa0908492
23. Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, Chou TH, Montefiori DC, Lu S. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 2005; 79:7933-7; PMID:15919951; http://dx.doi.org/10.1128/JVI.79.12.7933-7937.2005
24. Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol 2012; 61:935-43; PMID:22442293; http://dx.doi.org/10.1099/jmm.0.040857-0
25. Sharp FA, Ruane D, Claass B, Creagh E, Harris J, Malyala P, Singh M, O'Hagan DT, Pétrilli V, Tschopp J, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 2009; 106:870-5; PMID:19139407; http://dx.doi.org/10.1073/pnas. 0804897106
26. Hayday AC, Peakman M. The habitual, diverse and surmountable obstacles to human immunology research. Nat Immunol 2008; 9:575-80; PMID:18490903; http://dx.doi.org/10.1038/ni0608-575
27. Pal R, Yu Q, Wang S, Kalyanaraman VS, Nair BC, Hudacik L, Whitney S, Keen T, Hung CL, Hocker L, et al. Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits. Vaccine 2006; 24:1225-34; PMID:16219399; http://dx.doi.org/10.1016/j.vaccine.2005.07.112
28. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, et al.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013; 110:3507-12; PMID:23401516; http://dx.doi.org/10.1073/pnas.1222878110
29. Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D; Inflammation and the Host Response to Injury Investigators. Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol 2005; 12:60-7; PMID:15642986
30. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998; 9:143-50; PMID:9697844; http://dx.doi.org/10.1016/S1074-7613(00)80596-8
31. Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010; 28:2999-3007; PMID:20170767; http://dx.doi.org/10.1016/j.vaccine.2010.02.006